JP2020500193A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500193A5 JP2020500193A5 JP2019526314A JP2019526314A JP2020500193A5 JP 2020500193 A5 JP2020500193 A5 JP 2020500193A5 JP 2019526314 A JP2019526314 A JP 2019526314A JP 2019526314 A JP2019526314 A JP 2019526314A JP 2020500193 A5 JP2020500193 A5 JP 2020500193A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- acid
- deuterated
- compound
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 17
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 8
- 229960004488 linolenic acid Drugs 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 5
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 4
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 4
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims 4
- 229940033080 omega-6 fatty acid Drugs 0.000 claims 4
- 150000007970 thio esters Chemical class 0.000 claims 3
- KFINXCASWPGHEW-UHFFFAOYSA-N (9S*,10R*,11R*,12Z,15Z)-9,10,11-trihydroxyoctadeca-12,15-dienoic acid Natural products CCC=CCC=CC(O)C(O)C(O)CCCCCCCC(O)=O KFINXCASWPGHEW-UHFFFAOYSA-N 0.000 claims 2
- OYHQOLUKZRVURQ-ZVDPVMROSA-N (9z,12z)-11,11-dideuteriooctadeca-9,12-dienoic acid Chemical compound CCCCC\C=C/C([2H])([2H])\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-ZVDPVMROSA-N 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- MZQXAWAWDWCIKG-SPSBLGDNSA-N Avenoleic acid Chemical compound CCC[C@@H](O)C\C=C/C\C=C/CCCCCCCC(O)=O MZQXAWAWDWCIKG-SPSBLGDNSA-N 0.000 claims 2
- 102000009645 Mitochondrial Aldehyde Dehydrogenase Human genes 0.000 claims 2
- 108010009513 Mitochondrial Aldehyde Dehydrogenase Proteins 0.000 claims 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical class CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 claims 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 235000021342 arachidonic acid Nutrition 0.000 claims 1
- 229940114079 arachidonic acid Drugs 0.000 claims 1
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical group COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 150000002194 fatty esters Chemical class 0.000 claims 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 claims 1
- 229960004135 idebenone Drugs 0.000 claims 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130995A JP7464661B2 (ja) | 2016-11-17 | 2022-08-19 | 同位体修飾成分及びその治療上の使用 |
| JP2024052901A JP2024081733A (ja) | 2016-11-17 | 2024-03-28 | 同位体修飾成分及びその治療上の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423699P | 2016-11-17 | 2016-11-17 | |
| US62/423,699 | 2016-11-17 | ||
| PCT/US2017/062107 WO2018094116A1 (en) | 2016-11-17 | 2017-11-16 | Isotopically modified components and therapeutic uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130995A Division JP7464661B2 (ja) | 2016-11-17 | 2022-08-19 | 同位体修飾成分及びその治療上の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500193A JP2020500193A (ja) | 2020-01-09 |
| JP2020500193A5 true JP2020500193A5 (enExample) | 2020-12-17 |
| JP7132630B2 JP7132630B2 (ja) | 2022-09-07 |
Family
ID=62145748
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526314A Active JP7132630B2 (ja) | 2016-11-17 | 2017-11-16 | 同位体修飾成分及びその治療上の使用 |
| JP2022130995A Active JP7464661B2 (ja) | 2016-11-17 | 2022-08-19 | 同位体修飾成分及びその治療上の使用 |
| JP2024052901A Pending JP2024081733A (ja) | 2016-11-17 | 2024-03-28 | 同位体修飾成分及びその治療上の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130995A Active JP7464661B2 (ja) | 2016-11-17 | 2022-08-19 | 同位体修飾成分及びその治療上の使用 |
| JP2024052901A Pending JP2024081733A (ja) | 2016-11-17 | 2024-03-28 | 同位体修飾成分及びその治療上の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11166930B2 (enExample) |
| JP (3) | JP7132630B2 (enExample) |
| KR (1) | KR102580606B1 (enExample) |
| CN (1) | CN110167546A (enExample) |
| AU (2) | AU2017363147B2 (enExample) |
| WO (1) | WO2018094116A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10052299B2 (en) * | 2009-10-30 | 2018-08-21 | Retrotope, Inc. | Alleviating oxidative stress disorders with PUFA derivatives |
| CN110167546A (zh) | 2016-11-17 | 2019-08-23 | 乐巢拓普有限公司 | 同位素修饰的组分及其治疗用途 |
| US20210252173A1 (en) * | 2018-04-20 | 2021-08-19 | Retrotope, Inc. | Stabilized polyunsaturated compounds and uses thereof |
| CN109601803A (zh) * | 2018-11-07 | 2019-04-12 | 江西颐迪科技有限公司 | 一种能消除老年人体味并有助健康的饮料及其制作方法 |
| EP3880194A4 (en) * | 2018-11-15 | 2022-11-09 | Retrotope, Inc. | DEUTERED COMPOUNDS, COMPOSITIONS AND USES |
| BR112021019793A2 (pt) * | 2019-04-04 | 2021-12-07 | Dicerna Pharmaceuticals Inc | Composições e métodos para inibir expressão de gene no sistema nervoso central |
| CN116472023A (zh) * | 2020-02-12 | 2023-07-21 | 拜奥吉瓦有限责任公司 | 用于化妆品应用的氘代多不饱和脂肪酸或其酯 |
| CA3171330A1 (en) * | 2020-02-14 | 2021-08-19 | Retrotope, Inc. | Methods for treating tauopathy |
| WO2022170134A2 (en) * | 2021-02-05 | 2022-08-11 | Retrotope, Inc. | Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof |
| US11351143B1 (en) * | 2021-02-05 | 2022-06-07 | Retrotope, Inc. | Methods of treating amyotrophic lateral sclerosis |
| US11510889B2 (en) | 2021-02-05 | 2022-11-29 | Retrotope, Inc. | Methods for inhibiting the progression of neurodegenerative diseases |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
| US11491130B2 (en) | 2021-02-05 | 2022-11-08 | Retrotope, Inc. | Methods of treating amyotrophic lateral sclerosis |
| IL313592A (en) * | 2021-12-21 | 2024-08-01 | Biojiva Llc | Methods and preparations for the treatment of inflammatory disease |
| WO2023158641A1 (en) * | 2022-02-15 | 2023-08-24 | Retrotope, Inc. | Synergistic combination therapy for treating als |
| EP4627069A1 (en) * | 2022-12-01 | 2025-10-08 | Picoentech Co., Ltd. | Food and pharmaceutical composition for detoxifying endogenous aldehydes |
| KR20250110548A (ko) | 2024-01-12 | 2025-07-21 | 현대모비스 주식회사 | 전기자동차용 배터리팩 케이스 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030069208A1 (en) | 1997-11-25 | 2003-04-10 | University Of Otago | Mitochondrially targeted antioxidants |
| US6331532B1 (en) | 1998-11-25 | 2001-12-18 | University Of Otago | Mitochondrially targeted antioxidants |
| CA2337690C (en) | 1998-07-27 | 2013-10-01 | Texas Pharmaceuticals, Inc. | Chemically induced intracellular hyperthermia |
| US20060229278A1 (en) | 1998-11-25 | 2006-10-12 | Antipodean Pharmaceuticals, Inc. | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
| US20080275005A1 (en) | 1998-11-25 | 2008-11-06 | Murphy Michael P | Mitochondrially targeted antioxidants |
| US20070270381A1 (en) | 2000-05-25 | 2007-11-22 | Antipodean Pharmaceuticals, Inc. | Mitochondrially targeted antioxidants |
| US6544764B2 (en) * | 2000-11-14 | 2003-04-08 | Applera Corporation | Isolated human dehydrogenase proteins, nucleic acid molecules encoding these human dehydrogenase proteins, and uses thereof |
| US20030032078A1 (en) | 2001-01-23 | 2003-02-13 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of macular and retinal degenerations |
| NZ513547A (en) | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
| US7888334B2 (en) | 2003-08-22 | 2011-02-15 | Antipodean Pharmaceuticals, Inc. | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
| JP4648319B2 (ja) | 2003-08-22 | 2011-03-09 | アンティポディーン ファーマシューティカルズ インコーポレイティド | ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体 |
| WO2005033093A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| DK1909600T3 (da) * | 2005-07-29 | 2012-07-30 | Tima Foundation | Sammensætning til moderering af alkoholmetabolisme og til at reducere risikoen for alkoholforårsagede sygdomme |
| SI1933821T1 (sl) | 2005-09-15 | 2020-11-30 | Ptc Therapeutics, Inc. | Repne variante redoks-aktivnih terapevtikov za zdravljenje mitohondrijskih bolezni in drugih bolezni ter modulacijo energijskih biooznačevalcev |
| US8952071B2 (en) | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
| KR101715631B1 (ko) | 2008-04-01 | 2017-03-13 | 안티포딘 파마슈티칼스, 인코포레이티드 | 피부 관리를 위한 조성물 및 방법 |
| WO2009137045A2 (en) * | 2008-05-07 | 2009-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Crystal structure of aldehyde dehydrogenase and methods of use thereof |
| WO2010014758A1 (en) | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress |
| US10052299B2 (en) | 2009-10-30 | 2018-08-21 | Retrotope, Inc. | Alleviating oxidative stress disorders with PUFA derivatives |
| US20120005765A1 (en) * | 2010-07-01 | 2012-01-05 | Saint Louis University | Animal model for parkinson's disease |
| WO2012100347A1 (en) * | 2011-01-24 | 2012-08-02 | Inceptum Research & Therapeutics, Inc. | Compositions comprising a prostaglandin for treating neuropsychiatric conditions |
| WO2012148930A2 (en) * | 2011-04-26 | 2012-11-01 | Retrotope, Inc. | Oxidative retinal diseases |
| JP6106157B2 (ja) * | 2011-04-26 | 2017-03-29 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | 神経変性障害および筋疾患に関与するｐｕｆａ |
| JP6145087B2 (ja) * | 2011-04-26 | 2017-06-07 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | Ｐｕｆａ酸化関与障害 |
| CN110167546A (zh) | 2016-11-17 | 2019-08-23 | 乐巢拓普有限公司 | 同位素修饰的组分及其治疗用途 |
-
2017
- 2017-11-16 CN CN201780078162.9A patent/CN110167546A/zh active Pending
- 2017-11-16 KR KR1020197017162A patent/KR102580606B1/ko active Active
- 2017-11-16 AU AU2017363147A patent/AU2017363147B2/en active Active
- 2017-11-16 WO PCT/US2017/062107 patent/WO2018094116A1/en not_active Ceased
- 2017-11-16 US US16/348,087 patent/US11166930B2/en active Active
- 2017-11-16 JP JP2019526314A patent/JP7132630B2/ja active Active
-
2021
- 2021-10-27 US US17/512,531 patent/US20220133668A1/en not_active Abandoned
-
2022
- 2022-08-19 JP JP2022130995A patent/JP7464661B2/ja active Active
-
2023
- 2023-12-14 AU AU2023282263A patent/AU2023282263A1/en not_active Abandoned
-
2024
- 2024-03-28 JP JP2024052901A patent/JP2024081733A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500193A5 (enExample) | ||
| Schunck et al. | Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases | |
| Poorani et al. | COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance | |
| Calder | Fatty acids and inflammation: the cutting edge between food and pharma | |
| Konkel et al. | Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids | |
| Vanden Heuvel | Nutrigenomics and nutrigenetics of ω3 polyunsaturated fatty acids | |
| JP2014512351A5 (enExample) | ||
| Kaur et al. | Essential fatty acids as functional components of foods-a review | |
| Calder | Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases | |
| Yates et al. | Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease | |
| Panda et al. | PUFA, genotypes and risk for cardiovascular disease | |
| HRP20200068T1 (hr) | Etilni ester ikozapentaenske kiseline, namijenjen liječenju hipertrigliceridemije | |
| Serhan | Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators | |
| JP2012516852A5 (enExample) | ||
| JP2015527386A5 (enExample) | ||
| MX356427B (es) | Emulsion que contiene hormona. | |
| JP2011529503A5 (enExample) | ||
| JP2007504225A5 (enExample) | ||
| HRP20160939T1 (hr) | Pripravci za liječenje neuroloških poremećaja | |
| WO2008147562A3 (en) | Dietary formulations and methods for treatment of inflammation and other disorders | |
| JP2016501248A5 (enExample) | ||
| Proudman et al. | Dietary omega-3 fats for treatment of inflammatory joint disease: efficacy and utility | |
| JP2004217932A5 (enExample) | ||
| JP2007518764A5 (enExample) | ||
| DK1809125T3 (da) | Næringsmiddel, der indeholder en fedtblanding |